Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25332839 | 0.83 | ITGB3 (0.43) | TP53ITGB3ITGAVTSHRCYP3A4 | |
| SCHEMBL27819759 | 0.79 | TP53 (0.42) | TP53ITGB3ITGAVTSHRCYP3A4 | |
| SCHEMBL14159424 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TDP1 | |
| SCHEMBL29408015 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TDP1 | |
| SCHEMBL17295795 | 0.76 | SLC6A3 (0.41) | — | |
| SCHEMBL14678828 | 0.76 | CYP3A4 (0.46) | TP53ITGB3ITGAVTSHRCYP3A4 | |
| SCHEMBL15058059 | 0.76 | ALDH1A1 (0.32) | TP53ITGB3ITGAVTSHRALDH1A1 | |
| SCHEMBL17382863 | 0.76 | HSD17B10 (0.45) | ITGB3ITGAVTSHRCYP3A4HSD17B10 | |
| SCHEMBL29479345 | 0.76 | ALDH1A1 (0.32) | TP53ITGB3ITGAVTSHRALDH1A1 | |
| SCHEMBL20191922 | 0.76 | ALDH1A1 (0.42) | TP53TSHRCYP3A4HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115650925-B | Triazole alcohol derivative and preparation method and application thereof | 中国人民解放军海军军医大学 | 2024-09-24 | — | — | CN | disclosed |
| EP-4149933-B1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2024-06-12 | — | — | EP | disclosed |
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4149933-A1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | F. Hoffmann-La Roche AG (CH) | 2023-03-22 | — | — | EP | disclosed |
| CN-115650925-A | Triazole alcohol derivative and preparation method and application thereof | 中国人民解放军海军军医大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-115461337-A | Novel triazolyl derivatives as GABA A alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRA3, GABRB3 | TP53 4585/4885ITGB3 1994/4885ITGAV 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.